Novartis Suspends CAR-T Trials After Three Patient Deaths; Lilly Expands Deal Portfolio
Novartis has temporarily halted immunology and neuroscience studies of its experimental CAR-T therapy following the deaths of three patients. The company paused the trials after the safety incidents were reported by Endpoints News. The move comes as Eli Lilly completes its 13th acquisition of the year, though details on that deal were not provided in this brief.
Expanded Detail
EXPANDED:
The Swiss pharmaceutical company has paused its clinical trials for an experimental CAR-T treatment across two therapeutic areas. This decision follows the reported deaths of three participants, prompting a safety review. The halt was initiated after the incidents were brought to light by a trade
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Novartis and Bristol Myers pause CAR-T studies after fatal immune reactions · Drug development
Lilly expands immunology portfolio with $2.875B Merida deal · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more.” Browse more stories.